Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback